Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression Withdrawal in Renal Transplant
NCT00148252Phase 4Terminated
- Sponsor
- University of Oslo School of Pharmacy
- Start
- Feb 2003
- Primary completion
- Nov 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in kidney transplant rejection comparing MMF Withdrawal with CsA Withdrawal (2 arms). Primary endpoint: Absolute change in renal function (GFR Nankivell) at 12 months. Started Feb 2003; status: terminated.
02
Drugs
cyclosporinemycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00148252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148252.